Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Valeant
Biotech
Xenon frees itself of some XEN1101 milestone obligations
The agreement sees Xenon pay $6 million upfront to avoid having to hand over up to $40 million in milestones plus royalties down the line.
Nick Paul Taylor
Sep 11, 2018 9:55am
Nestlé to ax up to 450 skin health R&D jobs, exit facility
Sep 22, 2017 7:45am
Chutes & Ladders—BIO elects John Maraganore as new chair
Jun 22, 2017 4:08pm
Chutes & Ladders: Novo’s North American head exits after losing the CEO race
Mar 2, 2017 3:06pm
Chutes & Ladders: Allergan CEO Saunders adds chairman to title
Oct 28, 2016 9:32am
Chutes & Ladders: Valeant continues executive changes
Aug 12, 2016 8:16am
